- Novum IQ Infusion Platform now offers large volume and
syringe infusion smart pumps on an integrated system with shared
innovative digital health solutions to help enhance patient safety
and efficiency for clinicians
- Common user interface and connectivity across both pump
modalities are designed to help reduce workflow burden and allow
more time focused on patient care
Baxter International Inc. (NYSE:BAX), an innovative leader in
infusion therapies and technologies, today announced U.S. Food and
Drug Administration (FDA) 510(k) clearance of its Novum IQ
large volume infusion pump (LVP) with Dose IQ Safety
Software. Adding LVP modality to the Novum IQ Infusion
Platform – which includes Baxter’s syringe infusion pump (SYR) with
Dose IQ Safety Software, powered by the IQ Enterprise
Connectivity Suite – enables clinicians to utilize a single,
integrated system across a variety of patient care settings.
Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s
commitment to continued innovation in advancing infusion
therapy.
Heather Knight, executive vice president and group president,
Medical Products and Therapies at Baxter, highlighted the
customer-centric approach of the Novum IQ platform,
emphasizing its role in helping to enhance care delivery. “Our
goal, always, is to bring increased efficiency, safety and
opportunity for informed decision-making to our customers,
clinicians and the patients they serve,” Knight commented. “The
Novum IQ platform represents a meaningful shift in how
connected and intelligent infusion therapy can impact the way
clinicians provide care. Offering Novum IQ large volume and
syringe infusion pumps unlocks the potential of advanced, intuitive
technologies that customers seek to meet their needs.”
Enhancing Patient Care Efficiencies with Advanced Connected
Solutions
Health systems have experienced new and increased challenges
related to clinician turnover, burnout and staffing shortages1 in
addition to existing priorities focused on reducing cost and
improving patient outcomes. The Novum IQ Infusion Platform
integrates user experience across its LVP and SYR pumps and helps
to reduce the burden of non-critical tasks so that nurses,
pharmacists and other clinicians can spend more time focused on
patient care. Highlights of the platform include:
- Novum IQ LVP and Novum IQ SYR infusion pumps,
which share a common user interface designed to accomplish
association between a patient, medication and pump through a
digital on-screen barcode. The pumps’ integrated experience also
streamlines the training that clinicians need and helps reduce the
cognitive burden associated with understanding how to properly
operate multiple, disparate pump platforms.
- Dose IQ Safety Software, which features a web-based,
customizable drug library and dose error reduction system. Dose
IQ supports clinicians and hospitals by helping ensure pumps
are up to date with the latest, facility-specific drug and dosage
parameters and information through centralized access to current
drug library files. In addition, Dose IQ includes exclusive
titration error prevention technology designed to provide
additional safety measures.
- IQ Enterprise Connectivity Suite, a scalable all-in-one
server, integration engine and software application platform,
designed to simplify infusion system connectivity for the Novum
IQ Infusion Platform. The IQ Enterprise Suite enables:
- Full bi-directional electronic medical record (EMR)
interoperability with auto-programming and auto-documentation
capabilities.
- Enhanced Continuous Quality Improvement (CQI) reports that can
provide on-demand and actionable graphical views of infusion data
at the bedside.
- Over-the-air software updates, which could help save clinicians
time and enhance efficiency for biomedical engineers, who do not
need to remove pumps from the nursing floor for manual software and
firmware updates.
- Cybersecurity rigor, with Dose IQ Safety Software and
IQ Enterprise Connectivity Suite both certified to the UL
2900 Series of Standards.
Based on clinical setting and patient need, hospitals may need
and benefit from having access to both LVP and SYR pumps. Baxter’s
Novum IQ LVP supports the administration of high-volume
infusions at faster rates, while Novum IQ SYR supports the
delivery of small, precise amounts of fluid at lower rates, often
in pediatric, neonatal or anesthesia care settings.
The Novum IQ LVP and Novum IQ SYR are available to
order in the U.S. Baxter expects to expand the platform in the
future through continued product development and additional
regulatory submissions.
For more information on the Novum IQ LVP, please visit
www.NovumIQ.com.
About Baxter
Every day, millions of patients, caregivers and healthcare
providers rely on Baxter’s leading portfolio of diagnostic,
critical care, kidney care, nutrition, hospital and surgical
products used across patient homes, hospitals, physician offices
and other sites of care. For more than 90 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers who make it happen.
With products, digital health solutions and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and follow us on
X/Twitter, LinkedIn and Facebook.
Novum IQ LVP Indications for Use
The Novum IQ LVP is intended for use on adults and
pediatrics subpopulations, except for neonates, for the controlled
administration of fluids, pharmaceutical drugs, parenteral
nutrition, blood and blood products through the following
clinically accepted routes of administration: intravenous,
arterial, subcutaneous and epidural. The Novum IQ LVP is
intended for use on neonates, for the controlled administration of
fluids and parenteral nutrition through the following clinically
accepted routes of administration: intravenous and arterial. The
Novum IQ LVP is intended to be used in conjunction with
legally marketed and compatible administration sets, and
medications provided by the user. The Novum IQ LVP is
suitable for patient care in hospitals and outpatient health care
facilities. The Novum IQ LVP is intended to aid in the
reduction of operator interaction through guided programming,
including a way to automate the programming of infusion parameters
and documentation of infusion therapies when integrated with an
Electronic Medical Record (EMR) system. This automation is intended
to aid in the reduction of programming errors. The Novum IQ
LVP is intended to be used by trained healthcare professionals.
Novum IQ Syringe Pump Indications for Use
The Novum IQ syringe pump is intended to be used for the
controlled administration of fluids. These include pharmaceutical
drugs, parenteral nutrition, blood and blood products, and enteral
nutrition. The Novum IQ syringe pump is intended to deliver
an infusion through the following clinically accepted routes of
administration: intravenous, arterial, enteral, and subcutaneous.
The Novum IQ syringe pump is intended to be used in
conjunction with legally marketed and compatible administration
sets, syringes, and medications provided by the user. The Novum
IQ syringe pump is suitable for patient care in hospitals and
outpatient health care facilities. The Novum IQ syringe pump
is intended for use on adults, pediatrics and neonates. The
Novum IQ syringe pump is intended to aid in the reduction of
operator interaction through guided programming, including a way to
automate the programming of infusion parameters and documentation
of infusion therapies when integrated with an Electronic Medical
Record (EMR) system. This automation is intended to aid in the
reduction of programming errors. The Novum IQ syringe pump
is intended to be used by trained healthcare professionals.
Dose IQ Safety Software for Novum IQ LVP and Syringe Pump
Indications for Use
Dose IQ Safety Software is intended to be used with the
Novum IQ Syringe Pump and Novum IQ Large Volume Pump
to support the controlled administration of fluids. Dose IQ
Safety Software is intended to allow users to create and maintain
drug libraries, including the configuration of pump settings for
the compatible pumps. Dose IQ Safety Software is intended to
allow users to establish the facility-defined syringe list, which
is a subset of Baxter’s approved compatible syringes, for the
Novum IQ Syringe Pump. Dose IQ Safety Software is
intended to be used by licensed pharmacists. Dose IQ Safety
Software is intended to be used in hospitals and outpatient health
care facilities.
Rx only. For safe and proper use of the products
mentioned herein, please refer to the appropriate Operators
Manual.
This release includes forward-looking statements concerning
Novum IQ, Dose IQ and IQ Enterprise, including
potential benefits associated with their use. The statements are
based on assumptions about many important factors, including the
following, which could cause actual results to differ materially
from those in the forward-looking statements: demand for and market
acceptance for new and existing products; product development
risks, including satisfactory clinical performance and obtaining
and maintaining required regulatory approvals (including as a
result of evolving regulatory requirements); breaches or failures
of or vulnerabilities in the company's information technology
systems or products, including by cyber-attack, data leakage,
unauthorized access or theft; product quality, manufacturing or
supply, or patient safety issues; inability to create additional
production capacity in a timely manner or the occurrence of other
manufacturing or supply difficulties (including as a result of
natural disasters, public health crises and epidemics/pandemics,
regulatory actions or otherwise); actions of regulatory bodies and
other governmental authorities; changes in law and regulations; and
other risks identified in Baxter's most recent filing on Form 10-K
and other SEC filings, all of which are available on Baxter's
website. Baxter does not undertake to update its forward-looking
statements unless otherwise required by the federal securities
laws.
Baxter, Novum IQ, Dose IQ and IQ Enterprise are registered
trademarks of Baxter International Inc.
1
https://aspe.hhs.gov/sites/default/files/documents/9cc72124abd9ea25d58a22c7692dccb6/aspe-covid-workforce-report.pdf
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240401865359/en/
Media Contact Bess Featherstone McGuire, (224) 948-5353
media@baxter.com
Investor Contact Clare Trachtman, (224) 948-3020
Baxter (NYSE:BAX)
過去 株価チャート
から 12 2024 まで 1 2025
Baxter (NYSE:BAX)
過去 株価チャート
から 1 2024 まで 1 2025
